C
Charlotte Rolny
Researcher at Karolinska Institutet
Publications - 35
Citations - 5626
Charlotte Rolny is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Cancer & Tumor microenvironment. The author has an hindex of 21, co-authored 30 publications receiving 4732 citations. Previous affiliations of Charlotte Rolny include Ludwig Institute for Cancer Research & Uppsala University Hospital.
Papers
More filters
Journal ArticleDOI
Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq
Amit Zeisel,Ana B. Muñoz-Manchado,Simone Codeluppi,Peter Lönnerberg,Gioele La Manno,Anna Juréus,Sueli Marques,Hermany Munguba,Liqun He,Christer Betsholtz,Christer Betsholtz,Charlotte Rolny,Gonçalo Castelo-Branco,Jens Hjerling-Leffler,Sten Linnarsson +14 more
TL;DR: Large-scale single-cell RNA sequencing is used to classify cells in the mouse somatosensory cortex and hippocampal CA1 region and found 47 molecularly distinct subclasses, comprising all known major cell types in the cortex.
Journal ArticleDOI
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.
Charlotte Rolny,Massimiliano Mazzone,Sonia Tugues,Damya Laoui,Irja Johansson,Cathy Coulon,Mario Leonardo Squadrito,Inmaculada Segura,Xiujuan Li,Ellen Knevels,Sandra Costa,Stefan Vinckier,Tom Dresselaer,Peter Åkerud,Maria De Mol,Henriikka Salomäki,Mia Phillipson,Sabine Wyns,Erik G. Larsson,Ian Buysschaert,Johan Botling,Uwe Himmelreich,Jo A. Van Ginderachter,Michele De Palma,Mieke Dewerchin,Lena Claesson-Welsh,Peter Carmeliet +26 more
TL;DR: It is reported that the host-produced histidine-rich glycoprotein (HRG) inhibits tumor growth and metastasis, while improving chemotherapy, and offers therapeutic opportunities for anticancer and antiangiogenic treatment.
Journal ArticleDOI
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Anna-Maria Georgoudaki,Kajsa E. Prokopec,Vanessa F. Boura,Eva Hellqvist,Silke Sohn,Jeanette Östling,Rony Dahan,Robert A. Harris,Mattias Rantalainen,Daniel Klevebring,Malin Sund,Suzanne Egyhazi Brage,Jonas Fuxe,Charlotte Rolny,Fubin Li,Fubin Li,Jeffrey V. Ravetch,Mikael C. I. Karlsson +17 more
TL;DR: It is found that the pattern recognition scavenger receptor MARCO defines a subtype of suppressive TAMs and is linked to clinical outcome, and it is demonstrated that immunotherapies using antibodies designed to modify myeloid cells of the TME represent a promising mode of cancer treatment.
Journal ArticleDOI
The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration.
Kristina Holmqvist,Michael J. Cross,Charlotte Rolny,Robert Hägerkvist,Nader Rahimi,Taro Matsumoto,Lena Claesson-Welsh,Michael Welsh +7 more
TL;DR: It is demonstrated that Shb is important for VEGF signaling in endothelial cells by Shb binding to tyrosine 1175 in the VEGFR-2, which regulates V EGF-induced formation of focal adhesions and cell migration, of which the latter occurs in a phosphatidylinositol 3-kinase-dependent manner.
Journal ArticleDOI
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.
Sara Van de Veire,Ingeborg Stalmans,Femke Heindryckx,Hajimu Oura,Annemilaï Tijeras-Raballand,Thomas Schmidt,Sonja Loges,Imke Albrecht,Bart Jonckx,Stefan Vinckier,Christophe Van Steenkiste,Sonia Tugues,Sonia Tugues,Charlotte Rolny,Maria De Mol,Daniela Dettori,Patricia Hainaud,Lieve Coenegrachts,Jean Olivier Contreres,Tine Van Bergen,Henar Cuervo,Wei Hong Xiao,Carole Le Henaff,Ian Buysschaert,Behzad Kharabi Masouleh,Anja Geerts,Tibor Schomber,Philippe Bonnin,Vincent Lambert,Jurgen Haustraete,Serena Zacchigna,Jean-Marie Rakic,Wladimiro Jiménez,Agnès Noël,Mauro Giacca,Isabelle Colle,Jean-Michel Foidart,Gérard Tobelem,Manuel Morales-Ruiz,José Vilar,Patrick H. Maxwell,Stanley A. Vinores,Stanley A. Vinores,Geert Carmeliet,Mieke Dewerchin,Lena Claesson-Welsh,Evelyne Dupuy,Hans Van Vlierberghe,Gerhard Christofori,Massimiliano Mazzone,Michael Detmar,Desire Collen,Peter Carmeliet +52 more
TL;DR: It is shown that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease and warrant further testing of anti-PlGF therapies.